SK bioscience’s flu vaccine receives approval in Indonesia

SKYCellflu Quadrivalent. (SK bioscience)

SK bioscience Co. announced on Wednesday that its influenza vaccine, SKYCellflu Quadrivalent Prefilled Syringe, has been approved by the Indonesian Food and Drug Authority.

This marks the first time a domestically developed influenza vaccine has gained approval in Indonesia.

The World Health Organization (WHO) annually predicts the influenza strains circulating in both hemispheres, and Indonesia adheres to vaccination guidelines for both.

SK bioscience anticipates that since this approval pertains to the northern hemisphere vaccine, Indonesian health authorities will expedite the approval process for southern hemisphere influenza vaccines in the future.

Among influenza vaccines available in Korea, SKYCellflu is the only one utilizing cell culture technology and has also secured approvals in Malaysia, Thailand, Iran, and Chile.

The company aims to establish itself as a global vaccine brand, with various vaccines continuously obtaining WHO prequalification certification and approvals from multiple countries.